CAMPTOSAR

This brand name is authorized in Brazil, Ecuador, Mexico, New Zealand, United States

Active ingredients

The drug CAMPTOSAR contains one active pharmaceutical ingredient (API):

1 Irinotecan UNII 042LAQ1IIS - IRINOTECAN HYDROCHLORIDE

Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase I. Read about Irinotecan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CAMPTOSAR Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01CE02	Irinotecan	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CE Topoisomerase 1 (TOP1) inhibitors
Discover more medicines within L01CE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522212050053203, 522718010070817, 522718010070917
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 29326-08-10
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 431M97
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7841
Country: US	FDA, National Drug Code	Identifier(s): 0009-7529